Literature DB >> 1967312

Synthesis and structure-activity relationships of dynorphin A-(1-8) amide analogues.

H Yoshino1, T Nakazawa, Y Arakawa, T Kaneko, Y Tsuchiya, M Matsunaga, S Araki, M Ikeda, K Yamatsu, S Tachibana.   

Abstract

In order to study the structure-activity relationships of dynorphin A-(1-8) amide [Dyn(1-8)-NH2], 20 analogues were synthesized by the solution method. Their biological activities were determined in the three bioassays [guinea pig ileum (GPI), mouse vas deferens (MVD), and rabbit vas deferens (RVD)] and in the mouse tail-pinch test after intravenous administration. Some analogues that showed interesting activity in the bioassays and/or in the analgesic tests were further characterized in mu-, delta-, and kappa-representative binding assays. The obtained data indicate that modification of the enkephalin segment to give metabolically stable analogues with high affinity and selectivity for the kappa receptor is strictly limited and that introduction of MeArg in position 7 protects the Arg6-Arg-7 bond from enzymatic degradation without potency drop and change of opioid receptor selectivity. [MeTyr1,MeArg7,D-Leu8]Dyn(1-8)-NHEt (18) [IC50 (nM) = 0.3 (GPI), 7.4 (MVD), and 2.6 (RVD); tail pinch ED50 (mg/kg) = 0.75] showed opioid activity similar to that of dynorphin A in the three bioassays and relatively high kappa-receptor selectivity in the binding assays and produced a 2.5-fold more potent analgesic effect than morphine. [D-Cys2-Cys5,MeArg7,D-Leu8]Dyn(1-8)-NHEt (20) showed a 40-60-fold more potent opioid activity than 18 in the three bioassays and produced a 3.4-fold more potent analgesic effect than 18. In the binding assays, however, 20 showed higher affinity for mu and delta receptors than for the kappa receptor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1967312     DOI: 10.1021/jm00163a034

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

Review 1.  Dynorphin A analogs for the treatment of chronic neuropathic pain.

Authors:  Sara M Hall; Yeon Sun Lee; Victor J Hruby
Journal:  Future Med Chem       Date:  2016-01-29       Impact factor: 3.808

Review 2.  30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.

Authors:  Christoph Schwarzer
Journal:  Pharmacol Ther       Date:  2009-05-28       Impact factor: 12.310

3.  Long-lasting antinociceptive effects of a novel dynorphin analogue, Tyr-D-Ala-Phe-Leu-Arg psi (CH(2)NH) Arg-NH(2), in mice.

Authors:  M Hiramatsu; K Inoue; A Ambo; Y Sasaki; T Kameyama
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

4.  Stabilized dynorphin derivatives for modulating antinociceptive activity in morphine tolerant rats: effect of different routes of administration.

Authors:  Brugos Brugos; Vikram Arya; Guenther Hochhaus
Journal:  AAPS J       Date:  2004-12-28       Impact factor: 4.009

Review 5.  Peptide kappa opioid receptor ligands: potential for drug development.

Authors:  Jane V Aldrich; Jay P McLaughlin
Journal:  AAPS J       Date:  2009-05-09       Impact factor: 4.009

Review 6.  Cyclic Opioid Peptides.

Authors:  Michael Remesic; Yeon Sun Lee; Victor J Hruby
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 7.  Peptidomimetics and Their Applications for Opioid Peptide Drug Discovery.

Authors:  Yeon Sun Lee
Journal:  Biomolecules       Date:  2022-09-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.